Amicus Cash Flow Overview

FOLD Stock

USD 10.71 0.11 1.02%

Most accounts from Amicus Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Amicus Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Amicus Therapeutics Valuation and Amicus Therapeutics Correlation analysis.

For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

At present, Amicus Therapeutics' Change In Cash is projected to increase significantly based on the last few years of reporting. The current year's Depreciation is expected to grow to about 8.3 M, whereas Total Cash From Financing Activities is forecasted to decline to about 58.6 M.

For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.At present, Amicus Therapeutics' Change In Cash is projected to increase significantly based on the last few years of reporting. The current year's Depreciation is expected to grow to about 8.3 M, whereas Total Cash From Financing Activities is forecasted to decline to about 58.6 M.

Amicus Therapeutics cash flow statement Correlations

	Capital Expenditures	End Period Cash Flow	Change In Cash	Free Cash Flow	Change In Working Capital	Begin Period Cash Flow	Depreciation	Other Non Cash Items	Net Income	Change To Liabilities	Stock Based Compensation	Sale Purchase Of Stock	Change To Inventory	Investments	Change Receivables	Net Borrowings	Cash And Cash Equivalents Changes	Cash Flows Other Operating	Change To Account Receivables	Change To Netincome	Change To Operating Activities	Exchange Rate Changes	Issuance Of Capital Stock
Capital Expenditures		0.35	0.31	-0.56	0.1	0.14	0.3	0.19	-0.64	0.74	0.31	-0.02	-0.17	0.29	-0.36	0.01	0.21	-0.05	-0.4	0.29	-0.44	0.44	-0.17
End Period Cash Flow	0.35		0.59	-0.33	-0.64	0.55	0.87	-0.02	-0.46	-0.16	0.87	-0.41	-0.73	0.47	-0.63	0.18	0.02	0.23	-0.74	0.23	-0.66	0.69	-0.68
Change In Cash	0.31	0.59		0.04	0.05	-0.33	0.32	-0.52	-0.01	0.07	0.26	-0.28	-0.5	0.45	-0.04	0.25	0.54	0.59	-0.14	-0.42	0.02	0.03	-0.07
Free Cash Flow	-0.56	-0.33	0.04		0.12	-0.48	-0.45	-0.36	0.98	-0.48	-0.29	-0.31	-0.11	0.15	0.51	-0.48	-0.2	0.3	0.47	-0.48	0.48	-0.65	0.24
Change In Working Capital	0.1	-0.64	0.05	0.12		-0.72	-0.79	-0.28	0.24	0.62	-0.84	0.37	0.7	-0.19	0.78	0.0	0.64	0.07	0.8	-0.46	0.55	-0.73	0.78
Begin Period Cash Flow	0.14	0.55	-0.33	-0.48	-0.72		0.64	0.48	-0.57	-0.2	0.69	-0.18	-0.25	0.11	-0.65	0.01	-0.41	-0.32	-0.66	0.68	-0.78	0.73	-0.7
Depreciation	0.3	0.87	0.32	-0.45	-0.79	0.64		0.12	-0.57	-0.26	0.9	-0.36	-0.7	0.27	-0.78	0.28	-0.23	0.1	-0.86	0.36	-0.64	0.86	-0.85
Other Non Cash Items	0.19	-0.02	-0.52	-0.36	-0.28	0.48	0.12		-0.42	0.2	0.09	0.37	-0.02	-0.47	-0.2	-0.09	-0.53	-0.94	-0.22	0.96	-0.51	0.39	0.03
Net Income	-0.64	-0.46	-0.01	0.98	0.24	-0.57	-0.57	-0.42		-0.46	-0.45	-0.23	0.07	0.07	0.61	-0.4	-0.09	0.29	0.61	-0.56	0.6	-0.76	0.35
Change To Liabilities	0.74	-0.16	0.07	-0.48	0.62	-0.2	-0.26	0.2	-0.46		-0.26	0.35	0.32	-0.03	0.12	-0.1	0.41	-0.25	0.13	0.16	-0.16	0.02	0.41
Stock Based Compensation	0.31	0.87	0.26	-0.29	-0.84	0.69	0.9	0.09	-0.45	-0.26		-0.44	-0.8	0.45	-0.86	-0.05	-0.38	0.17	-0.94	0.34	-0.7	0.85	-0.86
Sale Purchase Of Stock	-0.02	-0.41	-0.28	-0.31	0.37	-0.18	-0.36	0.37	-0.23	0.35	-0.44		0.34	-0.81	0.23	0.21	0.01	-0.43	0.19	0.21	0.24	-0.13	0.55
Change To Inventory	-0.17	-0.73	-0.5	-0.11	0.7	-0.25	-0.7	-0.02	0.07	0.32	-0.8	0.34		-0.34	0.59	0.14	0.42	-0.22	0.73	-0.17	0.39	-0.56	0.55
Investments	0.29	0.47	0.45	0.15	-0.19	0.11	0.27	-0.47	0.07	-0.03	0.45	-0.81	-0.34		-0.3	-0.25	0.22	0.54	-0.25	-0.29	-0.28	0.13	-0.46
Change Receivables	-0.36	-0.63	-0.04	0.51	0.78	-0.65	-0.78	-0.2	0.61	0.12	-0.86	0.23	0.59	-0.3		-0.06	0.41	-0.03	0.96	-0.42	0.6	-0.89	0.76
Net Borrowings	0.01	0.18	0.25	-0.48	0.0	0.01	0.28	-0.09	-0.4	-0.1	-0.05	0.21	0.14	-0.25	-0.06		0.44	0.15	-0.05	-0.09	0.25	0.06	-0.14
Cash And Cash Equivalents Changes	0.21	0.02	0.54	-0.2	0.64	-0.41	-0.23	-0.53	-0.09	0.41	-0.38	0.01	0.42	0.22	0.41	0.44		0.39	0.44	-0.53	0.26	-0.38	0.34
Cash Flows Other Operating	-0.05	0.23	0.59	0.3	0.07	-0.32	0.1	-0.94	0.29	-0.25	0.17	-0.43	-0.22	0.54	-0.03	0.15	0.39		-0.05	-0.85	0.41	-0.19	-0.27
Change To Account Receivables	-0.4	-0.74	-0.14	0.47	0.8	-0.66	-0.86	-0.22	0.61	0.13	-0.94	0.19	0.73	-0.25	0.96	-0.05	0.44	-0.05		-0.44	0.64	-0.92	0.79
Change To Netincome	0.29	0.23	-0.42	-0.48	-0.46	0.68	0.36	0.96	-0.56	0.16	0.34	0.21	-0.17	-0.29	-0.42	-0.09	-0.53	-0.85	-0.44		-0.73	0.61	-0.21
Change To Operating Activities	-0.44	-0.66	0.02	0.48	0.55	-0.78	-0.64	-0.51	0.6	-0.16	-0.7	0.24	0.39	-0.28	0.6	0.25	0.26	0.41	0.64	-0.73		-0.78	0.51
Exchange Rate Changes	0.44	0.69	0.03	-0.65	-0.73	0.73	0.86	0.39	-0.76	0.02	0.85	-0.13	-0.56	0.13	-0.89	0.06	-0.38	-0.19	-0.92	0.61	-0.78		-0.7
Issuance Of Capital Stock	-0.17	-0.68	-0.07	0.24	0.78	-0.7	-0.85	0.03	0.35	0.41	-0.86	0.55	0.55	-0.46	0.76	-0.14	0.34	-0.27	0.79	-0.21	0.51	-0.7

Click cells to compare fundamentals

Amicus Therapeutics Account Relationship Matchups

Amicus Therapeutics cash flow statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Capital Expenditures	20.0M	3.2M	3.9M	3.8M	7.4M	4.3M
End Period Cash Flow	146.3M	166.2M	249.5M	153.1M	247.0M	259.3M
Change In Cash	64.0M	19.8M	83.3M	(96.3M)	98.2M	103.1M
Free Cash Flow	(270.4M)	(236.5M)	(206.4M)	(170.3M)	(76.5M)	(80.4M)
Depreciation	4.8M	8.8M	6.2M	5.3M	7.9M	8.3M
Other Non Cash Items	46.6M	17.8M	2.5M	28.0M	41.5M	25.3M
Net Income	(356.4M)	(276.9M)	(250.5M)	(236.6M)	(151.6M)	(159.2M)
Change To Inventory	(5.1M)	(4.6M)	(7.8M)	(5.3M)	(44.6M)	(42.4M)
Investments	115.2M	(10.4M)	82.6M	92.7M	55.3M	58.1M
Change Receivables	(11.1M)	(11.2M)	(8.2M)	(17.3M)	(15.6M)	(14.8M)
Net Borrowings	(420K)	230.7M	(479K)	(283K)	(325.5K)	(309.2K)
Change To Netincome	88.2M	59.7M	64.6M	77.6M	89.2M	61.4M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:

How To Invest In Amicus

Details

Is Amicus Stock a good investment?

Details

What is Amicus Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Amicus Therapeutics Valuation and Amicus Therapeutics Correlation analysis.

For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for Amicus Stock analysis

When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Transaction History View history of all your transactions and understand their impact on performance
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities

Is Amicus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.50)

Revenue Per Share

1.353

Quarterly Revenue Growth

0.306

Return On Assets

(0.06)

Return On Equity

(1.07)

The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Amicus Cash Flow Overview

Amicus Therapeutics cash flow statement Correlations

Amicus Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Amicus Therapeutics cash flow statement Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Amicus Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Income	+ 0.98	Free Cash Flow
Change To Netincome	+ 0.96	Other Non Cash Items
Change To Account Receivables	+ 0.96	Change Receivables
Stock Based Compensation	+ 0.9	Depreciation
Depreciation	+ 0.87	End Period Cash Flow
Stock Based Compensation	+ 0.87	End Period Cash Flow

Change To Account Receivables	- 0.94	Stock Based Compensation
Cash Flows Other Operating	- 0.94	Other Non Cash Items
Exchange Rate Changes	- 0.92	Change To Account Receivables
Exchange Rate Changes	- 0.89	Change Receivables
Issuance Of Capital Stock	- 0.86	Stock Based Compensation
Change Receivables	- 0.86	Stock Based Compensation